

## State Fiscal Year 2020 Supplemental Rebate Agreement Reporting

Nevada Revised Statutes Chapter 422.4025, Section 6 requires reporting concerning the financial effects of obtaining prescription drugs through health plan benefits to be posted on the Department of Health and Human Services website.

In Nevada, three managed care organizations enter into rebate agreements to purchase prescription drugs for health plans under the Medicaid program. A pharmacy benefit manager enters into rebate agreements on behalf of the fee-for-service Medicaid program. A summary of these agreements is provided in the table below.

**Table 1**

<b>Summary of Supplemental Rebate Agreements for Health Plans in SFY2020</b>		
<b>Health Plan</b>	<b>Number of Manufacturers Under Contract</b>	<b>Contract Value</b>
Anthem	130	\$3,945,103.51
Health Plan of Nevada	46	\$8,603,399.40
SilverSummit Healthplan	106	\$945,758.73
<b>Total Contract Value of All Health Plans</b>	-	<b>\$13,494,261.64</b>
Fee-for-Service Medicaid	36	\$7,661,308.26
<b>Total Contract Value for all of Nevada Medicaid</b>	-	<b>\$21,155,569.90</b>

Each of these managed care organizations has provided additional information specific to their health plan's supplemental rebate agreements in the following order:

- Anthem (pages 2 – 13)
- Health Plan of Nevada (pages 14-17)
- SilverSummit Healthplan (pages 18-25)

Additional information specific to supplemental rebate agreements related to prescription drugs for fee-for-service Medicaid recipients is provided by a single pharmacy benefit manager vendor:

- Optum Rx (pages 26- 32)

Please refer to the following pages of this document for details regarding manufacturer names, contract term dates, and contract values for individual, deidentified supplement rebate agreements.

Nevada Medicaid receives rebates on prescription drugs under two different programs. The Federal Medicaid Drug Rebate Program (MDRP) provides for Federally mandated rebates. The Nevada Medicaid Supplemental Rebate Program (NMSRP), pursuant to paragraph (b) of subsection 1 in section 31.4 of Senate Bill 378. (SB378), provides for Nevada-specific rebates that are in addition, or supplement, the Federally mandated rebates.

Created by the Omnibus Reconciliation Act of 1990 (OBRA 1990), the MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers must enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

In addition to the Federal rebate under the NDRA, state Medicaid agencies have the availability to collect additional rebates from manufacturers (e.g., supplemental). As set out above, the supplemental rebate program for Nevada Medicaid operates pursuant to SB378. The supplemental rebate does not reduce what is being paid under the NDRA, but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists.

The NMSRP has been in effect since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on Jan 31<sup>st</sup> and terminating on Dec 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes (NDC) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-Dec 31<sup>st</sup> end date, such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During State Fiscal Year 2020, the rebates negotiated under the NMSRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under SB378 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- “Percentage of WAC” — set percentage of the drug’s published wholesale acquisition cost (WAC).
- “Guaranteed Net Unit Price” (GNUP) WAC minus the Federal URA minus the GNUP.

Anthem Blue Cross and Blue Shield Healthcare Solutions is the trade name of Community Care Health Plan of Nevada, Inc., an independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

- In the event a drug’s WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
- Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with Anthem Blue Cross Blue Shield Healthcare Solutions.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing-related terms and conditions.

Anthem had 71 (222) SRAs in place that were in effect during a portion of State Fiscal Year 2020 (July 1, 2019 – June 30, 2020) (hereinafter referred to as SFY 2020). Table 1 below summarizes the agreements:

Table 1 Column Definitions:

- Number of Contracts — The count of signed SRAs that were in force during some period within SFY 2020.
- Number of Manufacturers Under Contract — The count of unique manufacturers with a signed SRA in force during some period within SFY 2020.
- SFY 2020 Amount Anthem Medicaid Paid Providers for Products Under Contract During Contract Term — The amount Anthem Medicaid paid to providers for drugs subject to a manufacturer’s SRA during SFY 2020.
  - Example: Drug “A” was subject to an SRA from 1/1/2019 to 12/31/2019, but not under an agreement in 2020. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 7/1/2019 to 12/31/2019.
- Contract Value During SFY 2020 — The supplemental rebate amount invoiced during SFY 2020 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products — The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Anthem Supplemental Rebate Agreements in Place during SFY 2020				
Number of Contracts	Number of Manufacturers Under Contract	SFY 2020 Amount Anthem Medicaid Paid Providers for Products Under Contract During Contract Term	Contract Value During SFY 2020	Supplemental Rebate Percentage of Drug Spend for Contracted Products
217	130	\$81,633,838.14	\$3,945,103.51	4.83%

Table 2 below lists the SRAs in place during SFY 2020. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name — The name of the entity the State has contracted within the SRA
- Contract Term — The effective and termination dates of the SRA

Table 2

Anthem Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
ABBOTT DIABETES CARE	10/1/2013-12/31/2019
ABBOTT DIABETES CARE	1/1/2020-12/31/2022
ABBVIE INC	1/1/2017-12/31/9999
ACORDA THERAPEUTICS INC	1/1/2016-12/31/2019
ACORDA THERAPEUTICS INC	1/1/2020-12/31/2021
ACTELION PHARMACEUTICALS	7/1/2015-12/31/2019
ADAPT PHARMA INC	7/1/2016-12/31/2019
ADAPT PHARMA INC	1/1/20-12/31/9999
AERIE	4/1/2018-12/31/2019
AERIE	1/1/2020-12/31/9999
AKORN, INC	1/1/2014-12/31/2019
AKRIMAX PHARMACEUTICALS LLC	7/1/2017-12/31/2019
ALKERMES INC	4/1/2016-12/31/2019
ALKERMES INC	4/1/2020-12/31/2025
ALLERGAN PHARM	1/1/2018-12/31/2019
ALLERGAN PHARM	1/1/2020-12/31/9999
AMAG PHARMACEUTICALS, INC	7/1/2013-12/31/2019
AMAG PHARMACEUTICALS, INC	1/1/2020-12/31/9999
AMARIN	7/1/2015-12/31/2019
AMARIN	1/1/2020-12/31/9999
AMGEN	4/1/2014-12/31/2019
AMGEN	1/1/2020-12/31/2022
ANTARES PHARMA INC	4/1/2015-12/31/2019
ANTARES PHARMA INC	1/1/2020-12/31/9999
AQUA PHARMACEUTICALS	4/1/2016-12/31/2019
AQUA PHARMACEUTICALS	1/1/2020-3/31/2022
ARBOR	1/1/2012-12/31/2019

ARBOR	1/1/2020-12/31/2021
ARKRAY USA INC	10/1/2013-12/31/2019
ARKRAY USA INC	1/1/2020-12/31/2022
ASEGUA	1/1/2019-12/31/2019
ASEGUA	1/1/2020-12/31/9999
ASSERTIO	1/1/2019-12/31/2019
Anthem Nevada Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
ASSERTIO	1/1/2020-12/31/9999
ASTELLAS PHARMA US	1/1/2018-12/31/2019
ASTELLAS PHARMA US	1/1/2020-12/31/9999
ASTRA ZENECA	4/1/2014-12/31/2019
ASTRA ZENECA	1/1/2020-12/31/9999
AVANIR PHARMACEUTICALS	1/1/2014-12/31/2019
AVANIR PHARMACEUTICALS	1/1/2020-12/31/2023
AVION PHARMACEUTICALS	1/1/2013-12/31/2019
AVION PHARMACEUTICALS	1/1/2020-12/31/9999
BAYER	1/1/2017-12/31/2019
BAYER	1/1/2020-12/31/2022
BAYER DIAGNOSTICS	10/1/2013-12/31/2019
BAYER DIAGNOSTICS	1/1/2020-12/31/9999
BECTON DICKINSON	1/1/2015-12/31/2019
BECTON DICKINSON	1/1/2020-12/31/9999
BIODELIVERY SCIENCES INT	7/1/2019-12/31/9999
BIOGEN	8/1/2011-12/31/2019
BIOGEN	1/1/2020-12/31/9999
BIOHAVEN PHARMACEUTICALS	4/1/2020-12/31/2022
BOEHRINGER INGELHEIM	1/1/2017-12/31/2019
BOEHRINGER INGELHEIM	1/1/2020-12/31/9999
BRISTOL-MYERS SQUIBB	1/1/2017-12/31/2019
BRISTOL-MYERS SQUIBB	1/1/2020-12/31/9999
CELGENE CORP	1/1/2018-12/31/2019
CELGENE CORP	1/1/2020-12/31/2020
CHIESI USA	1/1/2020-12/31/9999
CLOVIS ONCOLOGY INC	1/1/2020-12/31/2021
COHERUS BIOSCIENCES	1/1/2020-12/31/9999
COLLEGIUM PHARMACEUTICALS	7/1/2019-12/31/9999
COVIS PHARMA	4/1/2019-12/31/2019
COVIS PHARMA	1/1/2020-12/31/9999
CUMBERLAND PHARMACEUTICALS	1/1/2016-12/31/2019
DAIICHI SANKYO	1/1/2017-12/31/2019
DERMIRA, INC	10/1/2018-12/31/2019

DERMIRA, INC	1/1/2020-12/31/9999
DEXCOM	4/1/2014-12/31/2019
DEXCOM	1/1/2020-12/31/9999
DIGESTIVE CARE	1/1/2015-12/31/2019
DIGESTIVE CARE	1/1/2020-12/31/9999
DUCHESNAY USA, INC	1/1/2016-12/31/2019
Anthem Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
DUCHESNAY USA, INC	1/1/2020-12/31/9999
EGALET CORPORATION	7/1/2017-12/31/2019
EGALET CORPORATION	1/1/2020-12/31/9999
EISAI INC	1/1/2018-12/31/2019
EISAI INC	1/1/2020-12/31/9999
ELI LILLY & COMPANY	1/1/2019-12/31/2019
ELI LILLY & COMPANY	1/1/2020-12/31/2021
EMD SERONO	1/1/2019- 12/12/31/2021
ENCORE DERMATOLOGY, INC	7/1/2019-12/31/2019
ENDO PHARMACEUTICAL SOLUTIONS	1/1/2018-12/31/2019
EXELIXIS INC	7/1/2017-12/31/2019
EXELTIS USA DERMATOLOGY	1/1/2017-12/31/2019
EXELTIS USA DERMATOLOGY	1/1/2020-12/31/9999
EYEVANCE	10/1/2019-12/31/2019
EYEVANCE	1/1/2020-12/31/2022
FERRING	10/1/2013-12/31/2019
FERRING	1/1/2020-12/31/9999
FOUGERA PHARMACEUTICALS INC	1/1/2020-12/31/9999
FRESENIUS USA	1/1/2019-12/31/2019
FRESENIUS USA	1/1/2020-12/31/2021
GALDERMA	7/1/2017-6/30/2021
GENENTECH	1/1/2015-12/31/2019
GENENTECH	1/1/2020-12/31/2021
GILEAD SCIENCES INC	1/1/2009-12/31/2019
GILEAD SCIENCES INC	1/1/2020-12/31/9999
GLAXO SMITHKLINE	1/1/2019-12/31/2021
GREENWICH BIOSCIENCES	1/1/2019-12/31/2019
GREENWICH BIOSCIENCES	1/1/2020-12/31/2021
GRIFOLS USA, LLC	1/1/2020-12/31/2022
HORIZON PHARMA USA, INC	1/1/2014-12/31/2019
HORIZON PHARMA USA, INC	1/1/2020-12/31/9999
IMPAX PHARMACEUTICALS	1/1/2016-12/31/2019
IMPAX PHARMACEUTICALS	1/1/2020-12/31/9999
INDIVIOR	7/1/2019-12/31/9999

INNOCUTIS HOLDINGS	4/1/2015-12/31/2019
INNOCUTIS HOLDINGS	1/1/2020-12/31/9999
INSMED	7/1/2019-12/31/9999
INSYS THERAPEUTICS, INC	1/1/2015-12/31/9999
IRONSHORE	10/1/2019-12/31/2019
IRONSHORE	1/1/2020-12/31/9999
Anthem Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
JAZZ	10/1/2019-12/31/2019
JAZZ	4/1/2020-12/31/2022
JOHNSON and JOHNSON	1/1/2017-12/31/2021
KERYX BIOPHARMACEUTICALS, INC	1/1/2019-12/31/2019
KERYX BIOPHARMACEUTICALS, INC	1/1/2020-12/31/9999
KOWA PHARMACEUTICALS	4/1/2009-12/31/2019
KOWA PHARMACEUTICALS	1/1/2020-12/31/2021
KYOWA KIRIN	1/1/2020-6/30/2022
LEO PHARMA, INC	4/1/2016-12/31/2019
LEO PHARMA, INC	1/1/2020-12/31/2022
LIFESCAN	1/1/2020-12/31/2021
MALLINCKRODT	1/1/2019-12/31/2019
MALLINCKRODT	10/1/2019-12/31/9999
MANNKIND CORPORATION	1/1/2018-12/31/2019
MANNKIND CORPORATION	1/1/2020-12/31/9999
MAYNE PHARMA	4/1/2015-12/31/2019
MAYNE PHARMA	1/1/2020-12/31/9999
MEDA PHARMACEUTICALS	4/1/2011-12/31/2019
MEDEXUS PHARMA	4/1/2015-12/31/2019
MELINTA THERAPEUTICS INC	10/1/2018-12/31/2019
MELINTA THERAPEUTICS INC	1/1/2020-12/31/9999
MERCK & CO, INC	4/1/2017-12/31/2019
MERCK & CO, INC	1/1/2020-12/31/2021
MILLICENT	1/1/2020-7/31/2022
MISSION	1/1/2019-12/31/2019
MISSION	1/1/2020-12/31/9999
MYLAN PHARMACEUTICALS INC	7/1/2015-12/31/2019
MYLAN PHARMACEUTICALS INC	1/1/2020-12/31/2022
NEOS THERAPEUTICS LP	5/1/2016-12/31/2019
NEOS THERAPEUTICS LP	1/1/2020-12/31/9999
NESTLE HEALTH SCIENCE	4/1/2014-12/31/2019
NESTLE HEALTH SCIENCE	1/1/2020-12/31/9999
NEUROCRINE BIOSCIENCES INC	1/1/2020-12/31/9999
NOVARTIS	1/1/2019-12/31/2019
NOVARTIS	1/1/2020-12/31/9999

NOVEN THERAPEUTICS LLC	1/1/2019-12/31/2019
NOVEN THERAPEUTICS LLC	1/1/2020-12/31/9999
NOVO NORDISK	7/1/2013-12/31/2021
NOVO NORDISK	1/1/20-12/31/21
OPKO PHARMACEUTICALS LLC	1/1/2017-12/31/2019
Anthem Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
OPKO PHARMACEUTICALS LLC	1/1/2020-12/31/9999
OPTINOSE US, INC	1/1/2018-12/31/2019
OREXO	7/1/2019-12/31/2021
OTSUKA	7/1/2016-12/31/2019
OTSUKA	1/1/2020-12/31/9999
PERNIX THERAPEUTICS, LLC	1/1/2016-12/31/2019
PERNIX THERAPEUTICS, LLC	1/1/2020-12/31/9999
PERRIGO	1/1/2016-12/31/2019
PERRIGO	1/1/2020-12/31/9999
PFIZER US PHARM	1/1/2019-12/31/2019
PFIZER US PHARM	1/1/2020-12/31/9999
PROCTER & GAMBLE	10/1/2003-12/31/2019
PROMIUS PHARMA, INC	7/1/2016-12/31/2019
PURDUE PHARMA	1/1/2014-12/31/2019
PURDUE PHARMA	10/1/2019-12/31/9999
RECKITT BENCKISER	4/1/2015-12/31/2019
RECKITT BENCKISER	1/1/2020-12/31/9999
RELYPSA, INC	1/1/2016-12/31/2019
RELYPSA, INC	1/1/2020-3/31/2022
RETROPHIN INC	7/1/2017-12/31/2019
RETROPHIN INC	1/1/2020-12/31/9999
ROCHE DIAGNOSTICS	1/1/2017-12/31/2019
ROCHE DIAGNOSTICS	1/1/2020-12/31/2022
SANDOZ INC	4/1/2015-09/30/2020
SANDOZ INC	4/1/2020-12/31/9999
SANOFI - AVENTIS	7/1/2013-12/31/2021
SCILEX PHARMACEUTICALS INC	7/1/2019-12/31/9999
SEBELA PHARMACEUTICALS INC	1/1/2017-12/31/2019
SEBELA PHARMACEUTICALS INC	1/1/2020-12/31/9999
SHIONOGI & COMPANY, INC	4/1/2016-12/31/2019
SHIONOGI & COMPANY, INC	1/1/2020-12/31/2020
SHIRE-RICHWOOD	1/1/2017-12/31/9999
SHIRE-RICHWOOD	8/1/2019-08/31/2021
SUN PHARMA INDUSTRIES INC	7/1/2018-12/31/2019
SUN PHARMA INDUSTRIES INC	1/1/2020-12/31/2022
SUNOVION	4/1/2012-12/31/2019



SUNOVION	1/1/2020-12/31/9999
SUPERNUS PHARMACEUTICALS, INC	1/1/2017-12/31/2021
SUPERNUS PHARMACEUTICALS, INC	1/1/2020-12/31/9999
SYNERGY	4/1/2017-12/31/2019
Anthem Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
TAKEDA	1/1/2017-12/31/2019
TAKEDA	10/1/2019-12/31/9999
TERSERA THERAPEUTICS	7/1/2018-12/31/2019
TERSERA THERAPEUTICS	1/1/2020-12/31/9999
TEVA	1/1/2019-12/31/2019
TEVA	1/1/2020-12/31/9999
THERAPEUTICSMD INC	7/1/2011-12/31/2019
TOLMAR PHARMACEUTICALS INC	7/1/2017-03/31/2021
TRIS PHARMA	7/1/2016-12/31/2019
TRIS PHARMA	1/1/2020-12/31/9999
TRIVIDIA HEALTH	1/1/2017-12/31/2019
TRIVIDIA HEALTH	1/1/2020-12/31/2022
UCB INC	1/1/2016-12/31/2019
UCB INC	1/1/2020-12/31/9999
UPSHER-SMITH	1/1/2020-12/31/9999
US WORLDMEDS, LLC	1/1/2018-12/31/2019
VALEANT PHARMACEUTICALS	4/1/2016-12/31/2019
VALEANT PHARMACEUTICALS	1/1/2020-12/31/9999
VERTICAL PHARMACEUTICALS	4/1/2016-12/31/2019
VERTICAL PHARMACEUTICALS	1/1/2020-12/31/9999
VIVUS	1/1/2020-12/31/9999
WOMENS CHOICE PHARMACEUTICALS	10/1/2013-12/31/2019
WOMENS CHOICE PHARMACEUTICALS	1/1/2020-12/31/9999
XERIS	03/1/2020-12/31/9999

Table 3 below provides the value for each individual SRA. In order to meet the reporting requirements of SB378 and to maintain the confidentiality required by the SRAs, the agreements have been masked to prevent release of specific details. The numbering of the SRA is random and not based on the order manufacturers are listed in Table 2. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Supplemental Rebate Agreement ID — An alias identification used to identify the SRA without violating the terms of the confidentiality provisions.

- SFY 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term — The amount Anthem Medicaid paid to the provider for drugs in SFY 2020 under contract during the term of the SRA.
  - Example: Drug “A” was subject to an SRA from 1/1/2019 to 12/31/2019 but not under a SRA in 2020. This column would include the amount Anthem Medicaid paid to providers for Drug “A” for claims paid from 7/1/2019 to 12/31/2019.
- Contract Value During SFY 2020 — The SRA invoiced during SFY 2020 to manufacturers for drugs subject to the SRA.

Table 3

Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020		
Supplemental Rebate Agreement ID	Fiscal Year 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term	Contract Value During Fiscal Year 2020
1	\$39,279.60	\$0.00
2	\$10,113,831.72	\$917,103.95
3	\$7,506.86	\$0.00
4	\$614,421.70	\$0.00
5	\$108,891.53	\$9,856.67
6	\$19,657.67	\$0.00
7	\$14,366.97	\$0.00
8	\$239,943.86	\$0.00
9	\$516,354.72	\$53,850.66
10	\$3,018,763.99	\$0.00
11	\$238,619.39	\$78,924.65
12	\$144,395.78	\$0.00
13	\$2,302,590.48	\$483,712.50
14	\$28,409.02	\$0.00
15	\$12,709.56	\$0.00
16	\$159,923.29	\$0.00
17	\$276.91	\$0.00
18	\$1,767,257.14	\$251,895.60
19	\$154,288.21	\$0.00
20	\$136,773.49	\$0.00
21	\$1,288,606.91	\$0.00
22	\$29,989.71	\$0.00
23	\$3,055,012.91	\$153,633.08
24	\$14,112.28	\$0.00
25	\$34,114.95	\$0.00
26	\$45,555.64	\$0.00

27	\$347,260.38	\$24,548.94
28	\$91,646.67	\$0.00
29	\$1,910,690.56	\$21,151.79
30	\$16,541.40	\$0.00
Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020		
Supplemental Rebate Agreement ID	Fiscal Year 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term	Contract Value During Fiscal Year 2020
31	\$3,488,074.43	\$68,816.38
32	\$1,551,786.24	\$152,038.97
33	\$414,311.24	\$0.00
34	\$880,370.01	\$0.00
35	\$925.97	\$0.00
36	\$24,652.14	\$0.00
37	\$12,299.55	\$0.00
38	\$181,809.13	\$0.00
39	\$4,562.04	\$0.00
40	\$0.00	\$0.00
41	\$54,853.42	\$0.00
42	\$60,188.02	\$0.00
43	\$77,393.69	\$1,550.33
44	\$7,102.25	\$0.00
45	\$22,685.88	\$0.00
46	\$14,045.82	\$0.00
47	\$36,654.40	\$0.00
48	\$5,391,622.99	\$195,093.64
49	\$781,126.83	\$5,571.94
50	\$835.91	\$0.00
51	\$1,139.16	\$0.00
52	\$19,115.08	\$0.00
53	\$1,783.93	\$0.00
54	\$792.48	\$0.00
55	\$281,081.87	\$110,418.96
56	\$1,487.93	\$0.00
57	\$62,351.58	\$0.00
58	\$20,851.81	\$0.00
59	\$1,250,879.51	\$54,560.39
60	\$12,609,047.04	\$0.00
61	\$3,574,470.95	\$245,747.06
62	\$94,838.59	\$0.00
63	\$6,577.98	\$0.00
64	\$79,327.59	\$0.00

65	\$21,392.00	\$0.00
66	\$62,885.73	\$0.00
67	\$773.11	\$0.00
Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020		
Supplemental Rebate Agreement ID	Fiscal Year 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term	Contract Value During Fiscal Year 2020
68	\$6,800.30	\$0.00
69	\$4,724.09	\$0.00
70	\$113,807.46	\$0.00
71	\$5,285,861.05	\$37,281.22
72	\$18,806.40	\$0.00
73	\$49,964.68	\$0.00
74	\$6,280.44	\$0.00
75	\$21,506.76	\$0.00
76	\$22,615.49	\$0.00
77	\$622,018.41	\$0.00
78	\$37,627.65	\$0.00
79	\$13,161.47	\$0.00
80	\$2,211.45	\$0.00
81	\$982.06	\$0.00
82	\$26,787.43	\$0.00
83	\$2,443,476.36	\$55,002.69
84	\$524.24	\$0.00
85	\$783.73	\$0.00
86	\$11,663.62	\$0.00
87	\$5,777.51	\$0.00
88	\$3,601.35	\$243.32
89	\$197,647.69	\$0.00
90	\$723,219.92	\$585,663.32
91	\$948,829.98	\$13,820.90
92	\$7,304.40	\$0.00
93	\$3,812,462.17	\$286,275.06
94	\$18,015.32	\$0.00
95	\$477.11	\$0.00
96	\$6,785.63	\$0.00
97	\$2,450,146.76	\$107,199.68
98	\$24,668.18	\$0.00
99	\$952.40	\$0.00
100	\$1,302,462.07	\$0.00
101	\$0.00	\$0.00
102	\$1,343.45	\$0.00

103	\$129,373.60	\$0.00
104	\$352.90	\$62.07
<b>Anthem Supplemental Rebate Agreements in Place during Fiscal Year 2020</b>		
Supplemental Rebate Agreement ID	Fiscal Year 2020 Amount Anthem Medicaid Paid Providers for Drugs Under Contract During Contract Term	Contract Value During Fiscal Year 2020
105	\$5,101.34	\$0.00
106	\$29,771.81	\$0.00
107	\$11,372.75	\$0.00
108	\$38,269.46	\$10,587.49
109	\$293,181.10	\$0.00
110	\$7,974.29	\$0.00
111	\$8,284.48	\$0.00
112	\$1,270,770.18	\$10,462.13
113	\$19,851.01	\$0.00
114	\$2,428,950.19	\$0.00
115	\$102,204.12	\$0.00
116	\$4,005.60	\$0.00
117	\$416,093.29	\$0.00
118	\$6,393.89	\$0.00
119	\$260,764.15	\$0.00
120	\$116.54	\$0.00
121	\$13,286.44	\$0.00
122	\$18,901.73	\$0.00
123	\$31,179.25	\$0.00
124	\$8,444.59	\$0.00
125	\$741,627.45	\$9,213.56
126	\$25,476.85	\$0.00
127	\$524.28	\$0.00
128	\$1,826.36	\$816.56
129	\$553.86	\$0.00
130	\$0.00	\$0.00



# HEALTH PLAN OF NEVADA

A UnitedHealthcare Company

In compliance with the NRS 422.4025 adjustments effective 1/1/20, Health Plan of Nevada Medicaid has compiled the following report detailing the contractual rebate agreements and the blinded value of those rebates.

Health Plan of Nevada Medicaid had Supplemental Rebate Agreements (SRAs) in place with 46 manufacturers that were in effect during a portion of State Fiscal Year 2020 (July 1, 2019 – June 30, 2020) (hereinafter referred to as SFY 2020). Table 1 below summarizes the agreements:

**Table 1 Column Definitions:**

- Number of Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2020.
- Contract Value During SFY 2020 - The supplemental rebate amount invoiced during SFY 2020 to manufacturers for drugs subject to SRAs.

Table 1

Summary of Supplemental Rebate Agreements in Place during SFY 2020	
Number of Manufacturers Under Contract	Contract Value During SFY 2020
46	\$8,603,399.40

Table 2 below lists the SRAs in place during SFY 2020. The list is sorted alphabetically by manufacturer name.

**Table 2 Column Definitions:**

- Manufacturer Name - The name of the entity HPN has contracted with in the SRA
- Contract Term - The effective dates of the SRA during SFY 2020

Table 2

Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
ABBOTT DC	7/1/2019 - 6/30/2020
ABBVIE	7/1/2019 - 6/30/2020
ACTELION	7/1/2019 - 12/30/2019
ADAPT	7/1/2019 - 6/30/2020
AERIE	7/1/2019 - 6/30/2020
ALKERMES	7/1/2019 - 6/30/2020
AMGEN	7/1/2019 - 6/30/2020
ASEGUA	10/1/2019 - 6/30/2020
ASTRA ZENECA	7/1/2019 - 6/30/2020
BAUSCH HEALTH	4/1/2020 - 6/30/2020
BECTON DICKINSON	7/1/2019 - 6/30/2020
BIOGEN	7/1/2019 - 6/30/2020
BMS	7/1/2019 - 6/30/2020
BOEHRINGER INGLH	7/1/2019 - 6/30/2020
CELGENE	7/1/2019 - 3/30/2020
CHIESI	7/1/2019 - 6/30/2020

Good health takes a good plan.<sup>SM</sup>



**HEALTH PLAN OF NEVADA**  
A UnitedHealthcare Company

Table 2 continued

Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
DEY	7/1/2019 - 6/30/2020
ELI LILLY	7/1/2019 - 6/30/2020
FERRING	7/1/2019 - 6/30/2020
FRESENIUS KABI	7/1/2019 - 6/30/2020
GALDERMA	7/1/2019 - 6/30/2020
GILEAD	7/1/2019 - 6/30/2020
GSK	7/1/2019 - 6/30/2020
HIKMA	7/1/2019 - 6/30/2020
INDIVIOR	7/1/2019 - 3/30/2020
J&J	7/1/2019 - 6/30/2020
LIFESCAN	7/1/2019 - 6/30/2020
MERCK & CO INC	7/1/2019 - 6/30/2020
NOVARTIS	7/1/2019 - 6/30/2020
OTSUKA	7/1/2019 - 6/30/2020
PERNIX	7/1/2019 - 6/30/2020
PFIZER	7/1/2019 - 6/30/2020
RADIUS HEALTH	7/1/2019 - 6/30/2020
RELYPSA	7/1/2019 - 6/30/2020
SANDOZ	7/1/2019 - 6/30/2020
SANOFI-AVE	7/1/2019 - 6/30/2020
SHIONOGI PHARMA	7/1/2019 - 6/30/2020
SHIRE	7/1/2019 - 6/30/2020
SMITH&NEPHEW	7/1/2019 - 6/30/2020
SUNOVION	7/1/2019 - 6/30/2020
TAKEDA	10/1/2019 - 6/30/2020
TERSERA	7/1/2019 - 6/30/2020
THER-RX	7/1/2019 - 6/30/2020
UCB	7/1/2019 - 6/30/2020
VALEANT	7/1/2019 - 6/30/2020
VIIV	1/1/2020 - 6/30/2020

Good health takes a good plan.<sup>SM</sup>



**HEALTH PLAN OF NEVADA**  
A UnitedHealthcare Company

Table 3 below provides the value for each individual SRA. In order to meet the reporting requirements of SB378 and to maintain the confidentiality required by the SRAs, the agreements have been masked to prevent release of specific details. The numbering of the SRA is random and not based on the order manufacturers are listed in Table 2. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Supplemental Rebate Agreement ID - An alias identification used to identify the SRA without violating the terms of the confidentiality provisions.
- Contract Value During SFY 2020 - The SRA invoiced during SFY 2020 to manufacturers for drugs subject to the SRA.

Table 3

Supplemental Rebate Agreements in Place during Fiscal Year 2020	
Supplemental Rebate Agreement ID	Contract Value During Fiscal Year 2020
NVMCO HPN SRA 33	\$ 2,539,161.84
NVMCO HPN SRA 46	\$ 1,106,459.76
NVMCO HPN SRA 22	\$ 802,725.01
NVMCO HPN SRA 4	\$ 703,009.58
NVMCO HPN SRA 32	\$ 555,136.40
NVMCO HPN SRA 27	\$ 496,250.14
NVMCO HPN SRA 31	\$ 341,971.86
NVMCO HPN SRA 37	\$ 240,057.85
NVMCO HPN SRA 42	\$ 238,364.70
NVMCO HPN SRA 6	\$ 223,155.26
NVMCO HPN SRA 18	\$ 209,040.40
NVMCO HPN SRA 19	\$ 164,231.44
NVMCO HPN SRA 8	\$ 155,118.53
NVMCO HPN SRA 21	\$ 148,203.34
NVMCO HPN SRA 14	\$ 110,205.60
NVMCO HPN SRA 5	\$ 71,050.53
NVMCO HPN SRA 38	\$ 66,880.00
NVMCO HPN SRA 17	\$ 58,521.02
NVMCO HPN SRA 25	\$ 51,896.52
NVMCO HPN SRA 36	\$ 44,724.46
NVMCO HPN SRA 2	\$ 41,322.76
NVMCO HPN SRA 9	\$ 33,979.41
NVMCO HPN SRA 3	\$ 27,432.34
NVMCO HPN SRA 30	\$ 26,289.41
NVMCO HPN SRA 40	\$ 24,551.72

Good health takes a good plan.<sup>SM</sup>





HEALTH PLAN OF NEVADA  
A UnitedHealthcare Company

Table 3 continued

Supplemental Rebate Agreements in Place during Fiscal Year 2020	
Supplemental Rebate Agreement ID	Contract Value During Fiscal Year 2020
NVMCO HPN SRA 41	\$ 22,805.47
NVMCO HPN SRA 26	\$ 16,072.10
NVMCO HPN SRA 11	\$ 12,060.77
NVMCO HPN SRA 35	\$ 11,738.73
NVMCO HPN SRA 13	\$ 11,719.62
NVMCO HPN SRA 45	\$ 10,557.36
NVMCO HPN SRA 20	\$ 9,269.38
NVMCO HPN SRA 7	\$ 7,944.75
NVMCO HPN SRA 34	\$ 4,583.32
NVMCO HPN SRA 28	\$ 4,247.32
NVMCO HPN SRA 12	\$ 3,964.94
NVMCO HPN SRA 29	\$ 2,975.00
NVMCO HPN SRA 24	\$ 2,431.12
NVMCO HPN SRA 10	\$ 1,472.40
NVMCO HPN SRA 15	\$ 695.95
NVMCO HPN SRA 23	\$ 496.93
NVMCO HPN SRA 44	\$ 313.32
NVMCO HPN SRA 1	\$ 251.64
NVMCO HPN SRA 39	\$ 31.42
NVMCO HPN SRA 43	\$ 27.98
NVMCO HPN SRA 16	\$ -

Good health takes a good plan.<sup>SM</sup>



2500 N. Buffalo Drive  
Suite 250  
Las Vegas, NV 89128

## **Supplemental Rebate Agreement Report State Fiscal Year 2020 (July 1, 2019 to June 30, 2020)**

The Medicaid Drug Rebate Program (MDRP) is a collaborative program between the Centers for Medicare & Medicaid Services (CMS), state Medicaid Programs, and participating drug manufacturers. It was authorized by Section 1927 of the Social Security Act and was created through the Omnibus Reconciliation Act in 1990. The MDRP reduces the overall cost of medications for many Nevada Medicaid recipients.

Over 600 manufacturers currently participate in the MDRP and they have signed national agreements to provide these cost-saving drug rebates. Manufacturers are required to have a national rebate agreement in place and, in exchange, the state Medicaid programs include most of the manufacturer's products as covered medications. Manufacturers not participating in the MDRP have their medications excluded from coverage and reimbursement in Medicaid programs.

The Affordable Care Act (ACA) increased the amount of rebates for both brand and generic drugs and extended the rebates to include outpatient drugs covered by Medicaid managed care organizations like SilverSummit Healthplan (SSHP); the MDRP previously only applied to Medicaid benefits offered directly from the State. The Medicaid rebate formula varies by type of drug and is set by law to ensure that the Medicaid program generally receives the lowest price.

The CMS Medicaid Drug Rebate system performs the needed URA (unit rebate amount) calculations and the consumer price index urban (CPI-U) is an integral part of the URA computation. The MDRP rebates are collected and shared between the state and federal government based on federal medical assistance percentages (FMAP).

Supplemental Rebate Agreements (SRAs) are rebate agreements that are in addition to, or supplemental to, the rebates that are part of the MDRP. The supplemental rebate program for Nevada Medicaid operates pursuant to Senate Bill 378, a law passed in 2019.

Supplemental rebates do not affect or reduce the rebates provided to the State of Nevada through the MDRP, but they do provide additional value to help health plans to manage drug costs. Drug manufacturers enter into SRAs with Pharmacy Benefit Managers (PBM). SSHP uses Envolve Pharmacy Solutions (EPS) and CVS Caremark for their PBM services. CVS Caremark contracts with manufacturers for SRAs for drugs on the SSHP Preferred Drug List. SSHP leverages the CVS Caremark SRAs to collect supplemental rebates and CVS Caremark manages the supplemental rebate invoicing and collection on behalf of SSHP.

SRAs with CVS Caremark vary in length depending on the manufacturer. Manufacturer SRAs create incentives to encourage placement of their drugs as preferred drug(s) on the health plan's Preferred

Drug List (PDL). Supplemental rebates calculations are specified in the individual contracts but the majority of contracts calculate rebates based on:

*Percentage of WAC:* set percentage of the drug’s published wholesale acquisition cost (WAC).

All SRAs are confidential and proprietary between CVS Caremark and the manufacturer.

**Table 1 - Summary of Supplemental Rebate Agreements in Place during SFY 2020**

Number of Contracts	Number of Manufacturers Under Contract	SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term	Contract Value During SFY 2020	Supplemental Rebate Percentage of Drug Spend for Contracted Products
182	106	\$22,801,463.04	\$945,758.73	4.15%

Table 2 provides the list of SSHP’s applicable Supplemental Rebate Agreements in place during SFY 2020, sorted alphabetically by manufacturer. If a manufacturer had more than one Supplemental Rebate Agreement in place during SFY 2020, the contract term dates for each of those agreements are listed.

**Table 2 – Individual Supplemental Rebate Agreements in Place during SFY 2020**

Vendor Name	Contract Effective Date	Contract Expiration Date
ABBOTT DIABETES CARE	10/1/2013	12/31/2019
ABBOTT DIABETES CARE	1/1/2020	12/31/2022
ABBVIE INC	1/1/2017	12/31/9999 (auto renew)
ACTELION PHARMACEUTICALS	7/1/2015	12/31/2019
ADAPT PHARMA INC	7/1/2016	12/31/2019
ADAPT PHARMA INC	1/1/2020	12/31/9999 (auto renew)
AERIE	4/1/2018	12/31/2019
AERIE	1/1/2020	12/31/9999 (auto renew)
AKORN, INC	1/1/2014	12/31/2019
AKORN, INC	1/1/2020	12/31/2022
AKRIMAX PHARMACEUTICALS LLC	7/1/2017	12/31/2019
ALKERMES INC	4/1/2016	12/31/2019
ALKERMES INC	4/1/2020	12/31/2025
ALLERGAN PHARM	1/1/2018	12/31/2019
ALLERGAN PHARM	1/1/2020	12/31/9999 (auto renew)
AMAG PHARMACEUTICALS, INC	7/1/2013	12/31/2019
AMAG PHARMACEUTICALS, INC	1/1/2020	12/31/9999 (auto renew)
AMARIN	7/1/2015	12/31/2019
AMARIN	1/1/2020	12/31/9999 (auto renew)
AMGEN	4/1/2014	12/31/2019
AMGEN	1/1/2020	12/31/2022
ANTARES PHARMA INC	4/1/2015	12/31/2019
ANTARES PHARMA INC	1/1/2020	12/31/9999 (auto renew)

AQUA PHARMACEUTICALS	4/1/2016	12/31/2019
AQUA PHARMACEUTICALS	1/1/2020	3/31/2022
ARBOR	1/1/2012	12/31/2019
ARBOR	1/1/2020	12/31/2021
ARKRAY USA INC	10/1/2013	12/31/2019
ARKRAY USA INC	1/1/2020	12/31/2022
ASEGUA	1/1/2019	12/31/2019
ASEGUA	1/1/2020	12/31/9999 (auto renew)
ASSERTIO	1/1/2019	12/31/2019
ASSERTIO	1/1/2020	12/31/9999 (auto renew)
ASTELLAS PHARMA US	1/1/2018	12/31/2019
ASTELLAS PHARMA US	1/1/2020	12/31/9999 (auto renew)
ASTRA ZENECA	4/1/2004	12/31/2019
ASTRA ZENECA	1/1/2020	12/31/9999 (auto renew)
AVION PHARMACEUTICALS	1/1/2013	12/31/2019
AVION PHARMACEUTICALS	1/1/2020	12/31/9999 (auto renew)
BAYER	1/1/2017	12/31/2019
BAYER	1/1/2020	12/31/2022
BAYER DIAGNOSTICS	10/1/2013	12/31/2019
BAYER DIAGNOSTICS	1/1/2020	12/31/9999 (auto renew)
BECTON DICKINSON	1/1/2015	12/31/2019
BECTON DICKINSON	1/1/2020	12/31/9999 (auto renew)
BIODELIVERY SCIENCES INT	7/1/2019	12/31/9999 (auto renew)
BIOGEN	8/1/2011	12/31/2019
BIOGEN	1/1/2020	12/31/9999 (auto renew)
BIOHAVEN PHARMACEUTICALS	4/1/2020	12/31/2022
BOEHRINGER INGELHEIM	1/1/2017	12/31/2019
BOEHRINGER INGELHEIM	1/1/2020	12/31/9999 (auto renew)
BRISTOL-MYERS SQUIBB	1/1/2017	12/31/2019
BRISTOL-MYERS SQUIBB	1/1/2020	12/31/9999 (auto renew)
CELGENE CORP	1/1/2018	12/31/2019
CELGENE CORP	1/1/2020	12/31/2020
CELLTRION	10/1/2019	12/31/2022
COHERUS BIOSCIENCES	1/1/2019	12/31/2019
COLLEGIUM PHARMACEUTICALS	4/1/2016	9/30/2019
COLLEGIUM PHARMACEUTICALS	7/1/2019	12/31/9999 (auto renew)
COVIS PHARMA	4/1/2019	12/31/2019
COVIS PHARMA	1/1/2020	12/31/9999 (auto renew)
DAIICHI SANKYO	1/1/2017	12/31/2019
DAIICHI SANKYO	10/1/2019	12/31/2019
DERMIRA, INC	10/1/2018	12/31/2019
DERMIRA, INC	1/1/2020	12/31/9999 (auto renew)
DEXCOM	4/1/2014	12/31/2019
DEXCOM	1/1/2020	12/31/9999 (auto renew)
DUCHESNAY USA, INC	1/1/2016	12/31/2019
DUCHESNAY USA, INC	1/1/2020	12/31/9999 (auto renew)
ELI LILLY & COMPANY	1/1/2019	12/31/2019

ELI LILLY & COMPANY	1/1/2020	12/31/2021
EMD SERONO	1/1/2019	12/31/2021
EXELTIS USA DERMATOLOGY	1/1/2020	12/31/9999 (auto renew)
EYEVANCE	1/1/2020	12/31/2022
FERRING	10/1/2013	12/31/2019
FERRING	1/1/2020	12/31/9999 (auto renew)
GALDERMA	7/1/2007	6/30/2021
GENENTECH	1/1/2015	12/31/2019
GENENTECH	1/1/2020	12/31/2022
GENESIS HEALTH TECHNOLOGIES	8/1/2017	12/31/2019
GILEAD SCIENCES INC	1/1/2009	12/31/2019
GILEAD SCIENCES INC	1/1/2020	12/31/9999 (auto renew)
GLAXO SMITHKLINE	1/1/2019	12/31/2021
HORIZON PHARMA USA, INC	1/1/2014	12/31/2019
HORIZON PHARMA USA, INC	1/1/2020	12/31/9999 (auto renew)
IMPAX PHARMACEUTICALS	1/1/2016	12/31/2019
IMPAX PHARMACEUTICALS	1/1/2020	12/31/9999 (auto renew)
INDIVIOR	7/1/2019	12/31/9999 (auto renew)
IRONSHORE	1/1/2020	12/31/9999 (auto renew)
JOHNSON and JOHNSON	1/1/2017	12/31/2021
KALA PHARMACEUTICALS INC	1/1/2020	12/31/9999 (auto renew)
KERYX BIOPHARMACEUTICALS, INC	1/1/2019	12/31/2019
KERYX BIOPHARMACEUTICALS, INC	1/1/2020	12/31/9999 (auto renew)
KOWA PHARMACEUTICALS	4/1/2009	12/31/2019
KOWA PHARMACEUTICALS	1/1/2020	12/31/2021
LIFESCAN	1/1/2020	12/31/2021
MANNKIND CORPORATION	1/1/2018	12/31/2019
MANNKIND CORPORATION	1/1/2020	12/31/9999 (auto renew)
MAYNE PHARMA	4/1/2015	12/31/2019
MAYNE PHARMA	1/1/2020	12/31/9999 (auto renew)
MEDA PHARMACEUTICALS	4/1/2011	12/31/2019
MEDEXUS PHARMA	4/1/2015	12/31/2019
MEDEXUS PHARMA	1/1/2020	12/31/2021
MELINTA THERAPEUTICS INC	10/1/2018	12/31/2019
MELINTA THERAPEUTICS INC	1/1/2020	12/31/9999 (auto renew)
MERCK & CO, INC	4/1/2017	12/31/2019
MERCK & CO, INC	1/1/2020	12/31/2021
MISSION	1/1/2019	12/31/2019
MISSION	1/1/2020	12/31/9999 (auto renew)
MYLAN PHARMACEUTICALS INC	7/1/2015	12/31/2019
MYLAN PHARMACEUTICALS INC	1/1/2020	12/31/2022
NEOS THERAPEUTICS LP	5/1/2016	12/31/2019
NEOS THERAPEUTICS LP	1/1/2020	12/31/9999 (auto renew)
NESTLE HEALTH SCIENCE	1/1/2020	12/31/9999 (auto renew)
NEUROCRINE BIOSCIENCES INC	1/1/2020	12/31/9999 (auto renew)
NOVARTIS	1/1/2019	12/31/2019
NOVARTIS	1/1/2020	12/31/9999 (auto renew)

NOVEN THERAPEUTICS LLC	1/1/2019	12/31/2019
NOVEN THERAPEUTICS LLC	1/1/2020	12/31/9999 (auto renew)
NOVO NORDISK	7/1/2013	12/31/2021
NOVO NORDISK	1/1/2020	12/31/2021
OPKO PHARMACEUTICALS LLC	1/1/2017	12/31/2019
OPKO PHARMACEUTICALS LLC	1/1/2020	12/31/9999 (auto renew)
OREXO	7/1/2019	12/31/2021
OTSUKA	7/1/2016	12/31/2019
OTSUKA	1/1/2020	12/31/9999 (auto renew)
PERNIX THERAPEUTICS, LLC	1/1/2016	12/31/2019
PERNIX THERAPEUTICS, LLC	1/1/2020	12/31/9999 (auto renew)
PERRIGO	1/1/2016	12/31/2019
PERRIGO	1/1/2020	12/31/9999 (auto renew)
PFIZER US PHARM	1/1/2019	12/31/2019
PFIZER US PHARM	1/1/2020	12/31/9999 (auto renew)
PURDUE PHARMA	1/1/2014	12/31/2019
PURDUE PHARMA	10/1/2019	12/31/9999 (auto renew)
RADIUS HEALTH INC	4/1/2017	12/31/2019
RADIUS HEALTH INC	1/1/2020	12/31/9999 (auto renew)
RECKITT BENCKISER	4/1/2015	12/31/2019
RECKITT BENCKISER	1/1/2020	12/31/9999 (auto renew)
ROCHE DIAGNOSTICS	1/1/2017	12/31/2019
ROCHE DIAGNOSTICS	1/1/2020	12/31/2022
SANDOZ INC	4/1/2015	12/31/2019
SANDOZ INC	4/1/2020	12/31/9999 (auto renew)
SANOFI - AVENTIS	7/1/2013	12/31/2021
SCILEX PHARMACEUTICALS INC	7/1/2019	12/31/9999 (auto renew)
SEBELA PHARMACEUTICALS INC	1/1/2017	12/31/2019
SEBELA PHARMACEUTICALS INC	1/1/2020	12/31/9999 (auto renew)
SHIRE-RICHWOOD	1/1/2017	12/31/9999 (auto renew)
SUN PHARMA INDUSTRIES INC	7/1/2018	12/31/2019
SUN PHARMA INDUSTRIES INC	1/1/2020	12/31/2022
SUNOVION	4/1/2012	12/31/2019
SUNOVION	1/1/2020	12/31/9999 (auto renew)
SUPERNUS PHARMACEUTICALS, INC	1/1/2017	12/31/2021
SUPERNUS PHARMACEUTICALS, INC	1/1/2020	12/31/9999 (auto renew)
SYNERGY	4/1/2017	12/31/2019
TAKEDA	1/1/2017	9/30/2019
TAKEDA	10/1/2019	12/31/9999 (auto renew)
TERSERA THERAPEUTICS	7/1/2018	12/31/2019
TERSERA THERAPEUTICS	1/1/2020	12/31/9999 (auto renew)
TESARO, INC	4/1/2016	9/30/2020
TEVA	1/1/2019	12/31/2019
TEVA	1/1/2020	12/31/9999 (auto renew)
THERAPEUTICSMD INC	1/1/2020	12/31/9999 (auto renew)
TOLMAR PHARMACEUTICALS INC	7/1/2017	3/31/2021
TRIS PHARMA	7/1/2016	12/31/2019

TRIS PHARMA	1/1/2020	12/31/9999 (auto renew)
TRIVIDIA HEALTH	1/1/2017	12/31/2019
TRIVIDIA HEALTH	1/1/2020	12/31/2022
UCB INC	1/1/2016	12/31/2019
UCB INC	1/1/2020	12/31/9999 (auto renew)
UPSHER-SMITH	1/1/2020	12/31/9999 (auto renew)
US WORLDMEDS, LLC	1/1/2018	12/31/2019
VALEANT PHARMACEUTICALS	4/1/2016	12/31/2019
VALEANT PHARMACEUTICALS	1/1/2020	12/31/9999 (auto renew)
VELOXIS PHARMACEUTICALS	1/1/2020	12/31/9999 (auto renew)
VERTICAL PHARMACEUTICALS	4/1/2016	12/31/2019
VERTICAL PHARMACEUTICALS	1/1/2020	12/31/9999 (auto renew)
VIVUS	10/1/2013	12/31/2019
VIVUS	1/1/2020	12/31/9999 (auto renew)
WOMENS CHOICE PHARMACEUTICALS	10/1/2013	12/31/2019
WOMENS CHOICE PHARMACEUTICALS	1/1/2020	12/31/9999 (auto renew)

Table 3 provides the contract value for each manufacturer's Supplemental Rebate Agreement for SFY 2020, sorted from highest rebate value to lowest. To maintain confidentiality, the manufacturers' identities were replaced with a Supplemental Rebate Agreement ID number.

**Table 3 – Value of Each Individual Supplemental Rebate Agreement for SFY 2020**

Supplemental Rebate Agreement ID	SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term	Contract Value During SFY 2020
1	\$2,298,868.50	\$212,316.76
2	\$139,478.58	\$116,137.77
3	\$540,204.31	\$111,012.64
4	\$637,473.45	\$85,315.43
5	\$1,523,110.45	\$67,815.16
6	\$693,767.38	\$61,688.91
7	\$732,949.25	\$60,859.99
8	\$1,526,926.67	\$48,601.92
9	\$103,586.67	\$34,946.56
10	\$1,180,978.41	\$30,204.40
11	\$1,114,503.01	\$29,749.95
12	\$232,464.00	\$19,200.00
13	\$645,446.87	\$12,983.07
14	\$424,047.48	\$8,436.44
15	\$920,956.09	\$7,060.30
16	\$23,752.41	\$6,637.35
17	\$242,055.69	\$5,508.54
18	\$439,326.29	\$5,268.75
19	\$155,674.77	\$4,581.67
20	\$16,445.26	\$3,600.63
21	\$35,135.45	\$3,273.75

22	\$313,645.39	\$3,012.44
23	\$5,927.88	\$2,224.62
24	\$20,269.23	\$2,197.62
25	\$50,394.16	\$1,408.97
26	\$2,723.95	\$589.83
27	\$9,504.44	\$569.12
28	\$810.95	\$225.25
29	\$6,238.93	\$193.96
30	\$1,661.66	\$147.21
31	\$77.88	\$12.28
32	\$9,834.58	\$0.00
33	\$10,623.67	\$0.00
34	\$4,660.02	\$0.00
35	\$66,213.91	\$0.00
36	\$29,519.62	\$0.00
37	\$1,914.26	\$0.00
38	\$7,051.25	\$0.00
39	\$19,140.53	\$0.00
40	\$30.74	\$0.00
41	\$34,576.48	\$0.00
42	\$180,856.69	\$0.00
43	\$1,203,963.13	\$0.00
44	\$5,589.25	\$0.00
45	\$100,944.63	\$0.00
46	\$4,481.98	\$0.00
47	\$72,813.08	\$0.00
48	\$24,975.14	\$0.00
49	\$4,929.98	\$0.00
50	\$268,574.24	\$0.00
51	\$0.00	\$0.00
52	\$46,001.29	\$0.00
53	\$423.14	\$0.00
54	\$27,180.81	\$0.00
55	\$5,423.86	\$0.00
56	\$10,717.63	\$0.00
57	\$4,970.27	\$0.00
58	\$54,333.88	\$0.00
59	\$234.62	\$0.00
60	\$85.87	\$0.00
61	\$2,637.12	\$0.00
62	\$8,080.33	\$0.00
63	\$368,243.71	\$0.00
64	\$276.36	\$0.00
65	\$3,762,388.24	\$0.00
66	\$36,255.72	\$0.00
67	\$31,798.64	\$0.00
68	\$71,337.03	\$0.00



69	\$353.03	\$0.00
70	\$258.14	\$0.00
71	\$9,257.11	\$0.00
72	\$4,063.46	\$0.00
73	\$2,621.96	\$0.00
74	\$1,869.11	\$0.00
75	\$879.57	\$0.00
76	\$2,145.96	\$0.00
77	\$691.60	\$0.00
78	\$6,548.43	\$0.00
79	\$2,288.10	\$0.00
80	\$43,202.88	\$0.00
81	\$7,318.12	\$0.00
82	\$1,014.78	\$0.00
83	\$7,478.13	\$0.00
84	\$337.60	\$0.00
85	\$13,415.08	\$0.00
86	\$292.02	\$0.00
87	\$34,382.24	\$0.00
88	\$3,881.94	\$0.00
89	\$5,539.63	\$0.00
90	\$926,762.92	\$0.00
91	\$47,744.19	\$0.00
92	\$401.89	\$0.00
93	\$128,317.96	\$0.00
94	\$4,608.79	\$0.00
95	\$62,322.11	\$0.00
96	\$546.07	\$0.00
97	\$318.80	\$0.00
98	\$297.43	\$0.00
99	\$1,936.99	\$0.00
100	\$188,571.21	\$0.00
101	\$152.78	\$0.00
102	\$6,221.46	\$0.00
103	\$12,586.85	\$0.00
104	\$189.75	\$0.00
105	\$0.00	\$0.00
106	\$753,157.79	(\$22.56)
<b>Total Value</b>	<b>\$22,801,463.04</b>	<b>\$945,758.73</b>

*SilverSummit Healthplan is a managed care plan that delivers quality health insurance to the people of Nevada. Established in 2017, SilverSummit is committed to improving the health of its members through focused, compassionate, and coordinated care. SilverSummit's active community involvement reaches beyond physical and mental health. We are dedicated to improve the quality of life, one person at a time. SilverSummit Healthplan is a diversified healthcare organization that offers healthcare services through Nevada Medicaid, Medicare, and the Health Insurance Marketplace. For more information on SilverSummit, you may visit [www.silversummithealthplan.com](http://www.silversummithealthplan.com).*



## Nevada Medicaid Fee-for-Service Rebate Program

Nevada Medicaid receives rebates on prescription drugs under two different programs. The Federal Medicaid Drug Rebate Program (MDRP) provides for Federally mandated rebates. The Nevada Medicaid Supplemental Rebate Program (NMSRP), pursuant to paragraph (b) of subsection 1 in section 31.4 of Senate Bill 378. (SB378), provides for Nevada-specific rebates that are in addition, or supplement, the Federally mandated rebates.

Created by the Omnibus Reconciliation Act of 1990 (OBRA 1990), the MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. The National Drug Rebate Agreement (NDRA) is with the Secretary of the United States Department of Health and Human Services (HHS) and pharmaceutical manufacturers. The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRAs. The formulas for calculating the Federal unit rebate amount (URA) are set out by Federal statute.

In addition to the Federal rebate under the NDRA, state Medicaid agencies have the availability to collect additional rebates from manufacturers (e.g., supplemental). As set out above, the supplemental rebate program for Nevada Medicaid operates pursuant to SB378. The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists.

The NMSRP has operated as single state supplemental rebate program since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on January 1<sup>st</sup> and terminating on December 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new NDCs (National Drug Code) released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31<sup>st</sup> end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During State Fiscal Year 2020, the rebates negotiated under the NMSRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under SB378 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- “Percentage of WAC” - set percentage of the drug’s published wholesale acquisition cost (WAC).
- “GNUP” (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
  - In the event a drug’s WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
  - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a product is defined within a manufacturer’s SRA with Nevada Medicaid.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

Nevada Medicaid had seventy-one (71) SRAs in place that were in effect during a portion of State Fiscal Year 2020 (July 1, 2019 – June 30, 2020) (hereinafter referred to as SFY 2020). Table 1 below summarizes the agreements:

Table 1 Column Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within SFY 2020.
- Number of Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within SFY 2020.
- SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term - The amount Medicaid paid to providers for drugs subject to a manufacturer’s SRA during SFY 2020.
  - Example: Drug “A” was subject to an SRA from 01/01/2019 to 12/31/2019 but not under an agreement in 2020. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 07/01/19 to 12/31/19.
- Contract Value During SFY 2020 - The supplemental rebate amount invoiced during SFY 2020 to manufacturers for drugs subject to SRAs.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements in Place during SFY 2020				
Number of Contracts	Number of Manufacturers Under Contract	SFY 2020 Amount Medicaid Paid Providers for Products Under Contract During Contract Term	Contract Value During SFY 2020	Supplemental Rebate Percentage of Drug Spend for Contracted Products
71	36	\$53,466,912.33	\$7,661,308.26	14.3%

Table 2 below lists the SRAs in place during SFY 2020. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA
- Contract Term - The effective and termination dates of the SRA

Table 2

Supplemental Rebate Agreements in Place during SFY 2020

Manufacturer Name	Contract Term
ABBVIE US LLC	1/1/2019 - 12/31/2019
ABBVIE US LLC	1/1/2020 - 12/31/2020
AERIE PHARMACEUTICALS, INC.	1/1/2019 - 12/31/2019
AERIE PHARMACEUTICALS, INC.	9/1/2019 - 12/31/2019
AERIE PHARMACEUTICALS, INC.	1/1/2020 - 12/31/2020
ALLERGAN USA, INC.	1/1/2019 - 12/31/2019
ALLERGAN USA, INC.	1/1/2020 - 12/31/2020
AMGEN USA, INC.	1/1/2019 - 12/31/2019
AMGEN USA, INC.	8/1/2019 - 12/31/2019
AMGEN USA, INC.	1/1/2020 - 12/31/2020
ARBOR PHARMACEUTICALS, LLC	1/1/2019 - 12/31/2019
ASEGUA THERAPEUTICS, LLC	6/1/2019 - 12/31/2019
ASEGUA THERAPEUTICS, LLC	1/1/2020 - 12/31/2020
ASTRAZENECA PHARMACEUTICALS LP	1/1/2019 - 12/31/2019
ASTRAZENECA PHARMACEUTICALS LP	1/1/2020 - 12/31/2020
BAYER HEALTHCARE, LLC	1/1/2019 - 12/31/2019
BAYER HEALTHCARE, LLC	1/1/2020 - 12/31/2020
BIOGEN IDEC U.S. CORPORATION	1/1/2019 - 12/31/2019
BIOGEN IDEC U.S. CORPORATION	1/1/2020 - 12/31/2020
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	1/1/2019 - 12/31/2019

Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	1/1/2020 - 12/31/2020
BRISTOL-MYERS SQUIBB COMPANY	1/1/2019 - 12/31/2019
BRISTOL-MYERS SQUIBB COMPANY	1/1/2020 - 12/31/2020
CHIESI USA, INC.	1/1/2019 - 12/31/2019
CHIESI USA, INC.	1/1/2020 - 12/31/2020
DAIICHI SANKYO, INC.	1/1/2019 - 12/31/2019
DAIICHI SANKYO, INC.	1/1/2020 - 9/30/2020
DUCHESNAY USA	1/1/2019 - 12/31/2019
DUCHESNAY USA	1/1/2020 - 12/31/2020
EISAI INC	1/1/2019 - 12/31/2019
EISAI INC	1/1/2020 - 12/31/2020
ELI LILLY AND COMPANY	1/1/2019 - 12/31/2019
ELI LILLY AND COMPANY	1/1/2020 - 12/31/2020
GENZYME CORPORATION	1/1/2019 - 12/31/2019
GENZYME CORPORATION	7/1/2019 - 12/31/2019
GENZYME CORPORATION	1/1/2020 - 12/31/2020
GILEAD SCIENCES, INC.	1/1/2019 - 12/31/2019
GILEAD SCIENCES, INC.	1/1/2020 - 12/31/2020
GLAXOSMITHKLINE LLC	1/1/2019 - 12/31/2019
GLAXOSMITHKLINE LLC	1/1/2020 - 12/31/2020
INDEPENDENCE PHARMACEUTICALS, LLC	1/1/2019 - 12/31/2019
INDEPENDENCE PHARMACEUTICALS, LLC	1/1/2020 - 12/31/2020
INDIVIOR INC.	1/1/2019 - 12/31/2019
INDIVIOR INC.	6/1/2019 - 12/31/2019
INDIVIOR INC.	1/1/2020 - 12/31/2020
JANSSEN PHARMACEUTICALS, INC.	1/1/2019 - 12/31/2019
MERCK SHARP & DOHME CORP.	1/1/2019 - 12/31/2019
NOVARTIS PHARMACEUTICALS CORPORATION	1/1/2019 - 12/31/2019
NOVARTIS PHARMACEUTICALS CORPORATION	1/1/2020 - 12/31/2020
NOVO NORDISK INC.	1/1/2019 - 12/31/2019
NOVO NORDISK INC.	1/1/2020 - 12/31/2020
OREXO US, INC.	1/1/2019 - 12/31/2019
OTSUKA AMERICA PHARMACEUTICAL, INC.	1/1/2019 - 12/31/2019
OTSUKA AMERICA PHARMACEUTICAL, INC.	1/1/2020 - 12/31/2020
PARAPRO, LLC	1/1/2020 - 12/31/2020
PARI RESPIRATORY EQUIPMENT, INC.	1/1/2019 - 12/31/2019
PARI RESPIRATORY EQUIPMENT, INC.	1/1/2020 - 12/31/2020
PFIZER INC	1/1/2019 - 12/31/2019

Supplemental Rebate Agreements in Place during SFY 2020	
Manufacturer Name	Contract Term
PFIZER INC	1/1/2020 - 12/31/2020
SANOFI-AVENTIS US LLC	1/1/2019 - 12/31/2019
SANOFI-AVENTIS US LLC	1/1/2020 - 12/31/2020
SHIRE US, INC.	1/1/2019 - 12/31/2019
SHIRE US, INC.	1/1/2020 - 12/31/2020
SUNOVION PHARMACEUTICALS INC.	1/1/2019 - 12/31/2019
SUNOVION PHARMACEUTICALS INC.	2/1/2019 - 12/31/2019
SUNOVION PHARMACEUTICALS INC.	1/1/2020 - 12/31/2020
TEVA PHARMACEUTICALS USA, INC.	6/1/2020 - 3/31/2021
TRIS PHARMA	1/1/2019 - 12/31/2019
TRIS PHARMA	1/1/2020 - 12/31/2020
UCB, INC.	1/1/2019 - 12/31/2019
UCB, INC.	1/1/2020 - 12/31/2020

Table 3 below provides the value for each individual SRA. In order to meet the reporting requirements of SB378 and to maintain the confidentiality required by the SRAs, the agreements have been masked to prevent release of specific details. The numbering of the SRA is random and not based on the order manufacturers are listed in Table 2. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Supplemental Rebate Agreement ID - An alias identification used to identify the SRA without violating the terms of the confidentiality provisions.
- SFY 2020 Amount Medicaid Paid Providers for Drugs Under Contract During Contract Term - The amount Medicaid paid to the provider for drugs in SFY 2020 under contract during the term of the SRA.
  - Example: Drug “A” was subject to a SRA from 01/01/2019 to 12/31/2019 but not under a SRA in 2020. This column would include the amount Medicaid paid to providers for Drug “A” for claims paid from 07/01/2019 to 12/31/19.
- Contract Value During SFY 2020 - The SRA invoiced during SFY 2020 to manufacturers for drugs subject to the SRA.

Table 3

Supplemental Rebate Agreements in Place during Fiscal Year 2020		
Supplemental Rebate Agreement ID	Fiscal Year 2020 Amount Medicaid Paid Providers for Drugs Under Contract During Contract Term	Contract Value During Fiscal Year 2020
NVM SRA 7	\$5,499,021.61	\$2,331,283.07
NVM SRA 53	\$3,967,535.00	\$1,305,257.55
NVM SRA 39	\$920,295.17	\$320,244.42
NVM SRA 51	\$1,982,580.44	\$298,443.12
NVM SRA 26	\$996,696.72	\$285,791.23
NVM SRA 22	\$1,961,484.86	\$271,925.43
NVM SRA 3	\$1,585,993.42	\$236,081.34
NVM SRA 6	\$3,865,104.60	\$229,157.66
NVM SRA 21	\$515,390.12	\$223,863.64
NVM SRA 63	\$576,908.48	\$155,463.21
NVM SRA 23	\$3,082,181.91	\$150,348.73
NVM SRA 14	\$688,752.58	\$144,287.28
NVM SRA 44	\$1,517,890.55	\$128,648.69
NVM SRA 48	\$1,189,177.06	\$127,018.84
NVM SRA 10	\$209,187.70	\$109,944.64
NVM SRA 12	\$681,055.72	\$101,812.58
NVM SRA 24	\$503,965.42	\$96,638.98
NVM SRA 55	\$1,489,287.80	\$88,394.16
NVM SRA 62	\$644,776.82	\$86,950.18
NVM SRA 16	\$759,334.42	\$85,426.22
NVM SRA 45	\$495,229.52	\$74,443.82
NVM SRA 17	\$1,815,121.95	\$74,319.78
NVM SRA 15	\$879,030.12	\$65,930.03
NVM SRA 32	\$863,577.29	\$53,760.54
NVM SRA 37	\$1,993,161.04	\$53,026.39
NVM SRA 2	\$993,866.56	\$49,655.48
NVM SRA 40	\$164,914.69	\$41,746.35
NVM SRA 36	\$395,606.69	\$38,448.67
NVM SRA 60	\$856,755.57	\$36,383.44
NVM SRA 71	\$1,390,029.99	\$35,195.01
NVM SRA 18	\$200,621.44	\$34,668.86
NVM SRA 31	\$76,737.83	\$28,594.18
NVM SRA 41	\$1,306,120.76	\$28,165.26
NVM SRA 46	\$937,073.90	\$28,075.43
NVM SRA 33	\$1,854,627.69	\$26,421.86

Supplemental Rebate Agreements in Place during Fiscal Year 2020		
Supplemental Rebate Agreement ID	Fiscal Year 2020 Amount Medicaid Paid Providers for Drugs Under Contract During Contract Term	Contract Value During Fiscal Year 2020
NVM SRA 56	\$102,787.33	\$18,852.02
NVM SRA 11	\$1,345,310.84	\$18,445.86
NVM SRA 5	\$76,230.23	\$17,320.12
NVM SRA 61	\$423,105.63	\$17,252.72
NVM SRA 68	\$80,546.96	\$16,082.98
NVM SRA 47	\$236,541.37	\$15,494.45
NVM SRA 49	\$136,590.49	\$15,380.70
NVM SRA 29	\$129,945.12	\$14,526.70
NVM SRA 35	\$284,249.61	\$12,234.30
NVM SRA 57	\$126,744.91	\$10,156.81
NVM SRA 9	\$671,552.61	\$10,140.98
NVM SRA 67	\$298,294.00	\$8,893.99
NVM SRA 69	\$142,194.47	\$8,695.91
NVM SRA 20	\$34,817.45	\$7,932.02
NVM SRA 59	\$80,260.39	\$3,815.40
NVM SRA 1	\$160,654.24	\$3,569.56
NVM SRA 19	\$337,623.49	\$3,259.67
NVM SRA 66	\$12,012.56	\$3,057.09
NVM SRA 27	\$10,075.30	\$2,214.18
NVM SRA 58	\$14,190.30	\$2,166.70
NVM SRA 52	\$7,798.66	\$2,047.94
NVM SRA 28	\$4,069.44	\$1,766.87
NVM SRA 65	\$4,420.16	\$871.10
NVM SRA 64	\$51,709.50	\$531.77
NVM SRA 13	\$11,607.60	\$328.70
NVM SRA 4	\$1,102.44	\$294.72
NVM SRA 42	\$15,136.58	\$158.93
NVM SRA 38	\$1,119,192.83	\$0.00
NVM SRA 50	\$689,052.38	\$0.00
NVM SRA 25	\$0.00	\$0.00
NVM SRA 30	\$0.00	\$0.00
NVM SRA 34	\$0.00	\$0.00
NVM SRA 43	\$0.00	\$0.00
NVM SRA 54	\$0.00	\$0.00
NVM SRA 70	\$0.00	\$0.00
NVM SRA 8	\$0.00	\$0.00